XML 26 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Consolidated Statements of Operations [Abstract]      
Revenues $ 139,386 $ 166,819 $ 154,295
Cost of products sold 103,993 120,163 118,986
Gross profit 35,393 46,656 35,309
Operating expenses:      
Research and development (including $313, $409 and $448 of amortization of intangible assets, respectively) 8,595 8,755 9,451
Selling, general, and administrative (including $314, $408 and $496 of amortization of intangible assets, respectively) 24,323 26,039 29,407
Total operating expenses 32,918 34,794 38,858
Operating income (loss) 2,475 11,862 (3,549)
Other income (expense):      
Interest income 5   21
Interest expense (559) (1,138) (1,452)
Miscellaneous 171 145 (23)
Income (loss) from continuing operations before income taxes 2,092 10,869 (5,003)
Income tax provision (benefit)-current 32 (557) 31
Income tax provision-deferred 496 258 171
Total income taxes provision (benefit) 528 (299) 202
Net income (loss) from continuing operations 1,564 11,168 (5,205)
Discontinued operations:      
Loss from discontinued operations, net of tax (3,702) (17,377) (4,026)
Net income (loss) (2,138) (6,209) (9,231)
Net (income) loss attributable to noncontrolling interest 58 30 (10)
Net income (loss) attributable to Ultralife $ (2,080) $ (6,179) $ (9,241)
Net income (loss) attributable to Ultralife common shareholders-basic      
Continuing operations $ 0.09 $ 0.65 $ (0.31)
Discontinued operations $ (0.21) $ (1.01) $ (0.23)
Total $ (0.12) $ (0.36) $ (0.54)
Net income (loss) attributable to Ultralife common shareholders-diluted      
Continuing operations $ 0.09 $ 0.65 $ (0.31)
Discontinued operations $ (0.21) $ (1.01) $ (0.23)
Total $ (0.12) $ (0.36) $ (0.54)
Weighted average shares outstanding-basic 17,304 17,157 16,989
Weighted average shares outstanding-diluted 17,336 17,166 16,989